This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipeline Under the terms of the agreement, Nxe...
NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development und...
DualityBio announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate ("ADC") trastuzumab pamirtecan ("T-Pam"...
NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced that it has entered into an exclusive dis...
Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, \announced a strategic collaboration with Precision Health Research...
Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access an...
Novonesis expands global footprint with acquisition of production facility in Southeast Asia Investment of around USD 50 million strengthens ferment...
A pivotal step in PharmaEssentia's dual-site U.S.-Taiwan manufacturing strategy, with 2027 operations in sight PharmaEssentia Corporation (TWS...
Global pharma major Lupin Limited (Lupin) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pha...
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversific...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and develo...
Meiji Seika Pharma Co., Ltd. announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company deve...
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation c...
© 2026 Biopharma Boardroom. All Rights Reserved.
